Targeting a Novel Shared Tumour-Specific Antigen with T Cell Receptor Transduced T Cells for the Treatment of Cancer

Time: 11:30 am
day: Day Two


  • Utilising transgenic T cell receptor (TCR)-based T cell therapies which are powerful to target TSAs
  • Representing tumour organoids as reliable and more physiologically relevant models to characterise TSA-specific TCRs in comparison to 2D established tumour cell lines